Agomab Reports Positive STENOVA Data For Ontunisertib

October 01, 2026 — 07:05 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - On Thursday, Agomab Therapeutics (AGMB) reported positive results from the 48-week open-label extension of the Phase 2a STENOVA study evaluating ontunisertib in patients with fibrostenosing Crohn's disease.

Ontunisertib is an investigational oral, gut-restricted ALK5 inhibitor designed to target fibrosis in the gastrointestinal tract.

Through up to 60 weeks, the treatment showed a favorable safety profile, with one FSCD-related endoscopic balloon dilation and no surgeries. At Week 48, 97% of evaluable patients were in clinical remission.

Agomab plans to initiate the global Phase 2b NOV-ERA study, expected to enroll about 320 patients, in the coming months.

AGMB closed Wednesday's trade at $11.10, up 5.41%. In the pre-market trading, the stock is trading at $11.25, up 1.35%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Agomab Reports Positive STENOVA Data For Ontunisertib

Tags

Latest Articles